The perceptual and behavioral effects of recent hallucinogen use, ranging from profound perceptual shifts to a distressing "bad trip" or, with PCP, significant agitation.
Medically reviewed by
Dr. Mihaela G.
Hallucinogen Intoxication describes the behavioral and perceptual changes that develop during or shortly after using LSD, psilocybin, mescaline, PCP, or related substances. Unlike most other substances in this manual, the intended, sought-after effect here, profound perceptual change, altered sense of self, vivid sensory experience, is itself the core feature of intoxication, rather than a side effect of pursuing some other primary effect like euphoria or sedation.
This same syndrome, though, exists on a spectrum that includes genuinely distressing presentations, the experience commonly called a “bad trip”, involving significant anxiety, paranoia, or terrifying perceptual distortions that can feel, in the moment, dangerous or never-ending, even though it is, with classic hallucinogens, virtually always time-limited and resolves completely as the substance is metabolized.
PCP intoxication stands somewhat apart from this picture, carrying a meaningfully different and more concerning risk profile, including significant agitation, aggression, and impaired judgment that can lead to genuine danger, both to the person intoxicated and to others nearby, a distinction important to understand clearly given how differently this substance’s intoxication picture can unfold compared to classic hallucinogens.
Perceptual changes
Perceptual alterations while fully awake and alert, including visual distortions, depersonalization, derealization, illusions, and hallucinations, alongside synesthesias (such as perceiving sounds as colors).
Autonomic and physical signs
Pupillary dilation, tachycardia, sweating, palpitations, blurred vision, tremors, and incoordination.
Anxiety and distress (“bad trip”)
For some, particularly with higher doses or unfamiliar, stressful settings, intoxication can produce significant anxiety, paranoia, or panic, sometimes accompanied by frightening perceptual distortions experienced as genuinely threatening in the moment.
PCP-specific signs
With PCP specifically, additional and distinct signs include nystagmus, significant hypertension or tachycardia, numbness or diminished pain response, ataxia, dysarthria, muscle rigidity, and, notably, significant agitation or violence, seizures, and, at high doses, coma.
Reality testing typically preserved
A clinically important feature with classic hallucinogens is that, despite vivid perceptual changes, awareness that these perceptions are substance-induced (intact reality testing) is generally preserved, distinguishing this from a true psychotic break, though this distinction can become less clear at very high doses or in vulnerable individuals.
⋅ A wide emotional range, from profound wonder and connectedness to significant anxiety or terror
⋅ Paranoia, particularly during a distressing intoxication experience
⋅ Emotional lability, shifting rapidly between intense states
⋅ With PCP, significant agitation or emotional volatility
⋅ Profound alterations in perception of self, time, and surroundings
⋅ Generally preserved awareness that experiences are substance-induced, with classic hallucinogens
⋅ Impaired judgment, particularly regarding safety-relevant decisions
⋅ With PCP, more significant cognitive disorganization and impaired judgment
⋅ Pupillary dilation, elevated heart rate, and sweating
⋅ Tremors and incoordination
⋅ With PCP, nystagmus, muscle rigidity, and diminished pain response
⋅ At high PCP doses, seizures or coma
⋅ Significant behavioral changes connected to altered perception and judgment
⋅ Risk-taking behavior connected to impaired judgment during intoxication
⋅ Withdrawal or significant distress-driven behavior during a difficult intoxication experience
⋅ With PCP specifically, agitation, aggression, or violent behavior
Intoxication occurs with the large majority of hallucinogen use, given that perceptual alteration is the substance’s primary, sought-after effect. Significantly distressing intoxication, the “bad trip” experience, is a recognized phenomenon reported by a meaningful proportion of users, though rates vary considerably depending on dose, setting, and individual factors.
Risk factors for a more distressing experience include higher doses, an unfamiliar or stressful setting, lack of trusted support during the experience, and a personal or family history of anxiety or psychotic disorders.
PCP intoxication carries a distinct, generally higher risk profile for severe behavioral disturbance and medical complications compared to classic hallucinogens, making this substance worth understanding as carrying meaningfully different acute risks within the same broader category.
Hallucinogen intoxication results from these substances’ action on specific neurotransmitter systems involved in perception, mood, and cognition, with classic hallucinogens and PCP working through notably different mechanisms.
Serotonin receptor activation, particularly involving a specific serotonin receptor subtype, underlies the perceptual and cognitive effects of classic hallucinogens like LSD and psilocybin, producing the altered sensory processing and sense of self characteristic of these substances.
Dose, setting, and expectation significantly shape whether an intoxication experience tends toward the profound and meaningful or the distressing and frightening; higher doses, unfamiliar or unsafe-feeling environments, and significant pre-existing anxiety are all associated with a higher likelihood of a difficult, rather than positive, experience.
PCP’s distinct glutamate receptor mechanism explains its different, generally more medically concerning intoxication profile, including the agitation, aggression, and diminished pain perception that distinguish it from classic hallucinogens, alongside genuine risk of seizures or coma at high doses.
Individual psychological vulnerability, particularly a personal or family history of anxiety or psychotic disorders, can increase susceptibility to a significantly distressing intoxication experience, and, in rare cases, contribute to longer-lasting psychological complications.
Hallucinogen Intoxication is diagnosed based on recent hallucinogen use, with clinically significant problematic behavioral or psychological changes developing during or shortly after use, alongside perceptual changes occurring in a state of full wakefulness and alertness, and two or more physiological signs developing during or shortly after use: pupillary dilation, tachycardia, sweating, palpitations, blurred vision, tremors, and incoordination. For PCP intoxication specifically, criteria additionally include signs such as nystagmus, hypertension, numbness or diminished pain response, ataxia, dysarthria, muscle rigidity, seizures or coma, and hyperacusis.
Differential diagnosis requires distinguishing this from a primary psychotic episode, particularly important given how vivid hallucinogen-induced perceptual changes can be; the connection to recent use and generally preserved reality testing, with classic hallucinogens, helps clarify this distinction, though this can become genuinely more difficult to assess at very high doses, in vulnerable individuals, or with PCP specifically, given its different, often more disorganizing effect on cognition.
Treatment for hallucinogen intoxication differs meaningfully between classic hallucinogens and PCP, given their distinct risk profiles.
Supportive care for classic hallucinogen intoxication
For the large majority of intoxication experiences, including most distressing “bad trips,” supportive care, a calm, safe environment, reassurance, and the presence of a trusted, sober person, is generally sufficient, often summarized as “talking someone down,” and symptoms resolve fully as the substance is metabolized.
Managing significant anxiety or panic
For significant anxiety or panic during intoxication, reducing environmental stimulation, gentle reassurance that the experience is temporary and substance-induced, and avoiding confrontational or frightening responses from those nearby, all support a better outcome.
Emergency care for PCP intoxication
Given PCP’s distinct risk profile, significant agitation, aggression, seizures, or very high doses require careful, sometimes urgent medical management, including, in some cases, medication to manage severe agitation, given both the safety risk to the person and to others nearby.
No specific reversal agent
As with several substances in this manual, there’s no medication that directly reverses classic hallucinogen intoxication; supportive care and time remain the primary approach for the large majority of presentations.
Addressing recurring distressing experiences
If significantly distressing intoxication experiences are recurring, this may warrant reassessing use patterns or evaluating for an underlying anxiety vulnerability that might benefit from direct attention.
If you’re supporting someone through a difficult hallucinogen experience, stay calm and provide reassurance. Reminding them gently that the experience is temporary and connected to the substance, while reducing overstimulation, is generally the most helpful approach for classic hallucinogens.
Recognize that distressing perceptual or emotional experiences during intoxication are temporary, even though they can feel intensely real in the moment. This understanding itself can ease some of the fear connected to a difficult experience.
Be aware that PCP intoxication carries meaningfully different and more serious risks than classic hallucinogens. Significant agitation, aggression, or seizures require urgent medical attention rather than simply supportive reassurance.
If you have a personal or family history of anxiety or psychosis, approach hallucinogen use with particular caution. This is a recognized risk factor for a more difficult or, rarely, more lasting adverse experience.
If distressing intoxication experiences are becoming a recurring pattern, take this as meaningful information. This might be worth discussing with a healthcare provider, both regarding your use patterns and any underlying anxiety that might benefit from direct attention.
The outlook for classic hallucinogen intoxication, including most distressing “bad trip” experiences, is excellent; symptoms resolve completely as the substance is metabolized, typically within several hours, without lasting physical harm.
PCP intoxication carries genuinely more serious risk, including potential for significant injury connected to agitation or aggression, and, at high doses, seizures or coma, requiring more careful, sometimes urgent, medical attention.
Rarely, particularly in vulnerable individuals or with very high doses, hallucinogen use can contribute to longer-lasting psychological complications, including Hallucinogen Persisting Perception Disorder or, in those with underlying vulnerability, a more prolonged psychotic episode, both warranting their own careful clinical attention beyond the acute intoxication period itself.
Seek a calm, supportive environment first for typical hallucinogen-related anxiety or distress, since this usually resolves with reassurance and time alone.
Seek immediate emergency care for significant agitation, aggression, seizures, or loss of consciousness, particularly with PCP use, given the genuinely more serious risk profile this substance carries.
Seek evaluation if perceptual disturbances or significant anxiety persist well beyond the expected duration of intoxication, since this might indicate a longer-lasting complication warranting its own specific attention.
Someone in your life might be quietly looking for this. Share it:
These conditions share overlapping symptoms and are often misdiagnosed.
A “bad trip” refers to a significantly distressing hallucinogen intoxication experience, often involving intense anxiety, paranoia, or frightening perceptual distortions. While it can feel genuinely terrifying or even dangerous in the moment, it’s almost always time-limited with classic hallucinogens like LSD or psilocybin and resolves completely as the substance is metabolized, generally without lasting physical harm, though the experience itself can be significantly distressing while it’s happening.
PCP works through a different neurotransmitter mechanism than classic hallucinogens and carries a notably more concerning risk profile, including significant agitation, aggression, diminished pain perception, and, at high doses, seizures or coma. This is meaningfully different from the more introspective, perceptually focused experience typical of LSD or psilocybin, and PCP intoxication generally requires more careful, sometimes urgent, medical attention as a result.
With classic hallucinogens, awareness that the perceptual changes are substance-induced is generally preserved, distinguishing this from a true psychotic break, even though the experiences themselves can be quite vivid and intense. This distinction can become less clear at very high doses or in people with underlying vulnerability to psychosis, which is part of why a personal or family history of psychotic disorders is an important consideration before using these substances.
For classic hallucinogens, providing calm reassurance, reducing overstimulation, and reminding them gently that the experience is temporary generally helps considerably, often described as “talking someone down.” This approach is appropriate for the large majority of difficult experiences. If significant agitation, aggression, or loss of consciousness occurs, particularly with PCP, seek emergency medical attention rather than relying on reassurance alone.
Halpern, J. H. (2003). Hallucinogens: an update. Current Psychiatry Reports, 5(5), 347–354. PubMed
Carbonaro, T. M., Bennett, B. C., Yu, C. K., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268–1278. PubMed
Bey, T., & Patel, A. (2007). Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug. California Journal of Emergency Medicine, 8(1), 9–14. PubMed
Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620. PubMed
Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. PubMed
